Lundbeck Nasdaq Copenhagen

LUN

DK0061804697

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimerâs disease, Bipolar disorder, depression, epilepsy, Huntingtonâs disease, Parkinsonâs disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimerâs disease, Azilect for the treatment of Parkinsonâs disease, Xenazine for the treatment of Huntingtonâs disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Lundbeck

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

32.54 DKK

Average target price

38.71 DKK

Spread / Average Target

+18.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
MCKESSON CORPORATION	+13.29%	68.18B
CARDINAL HEALTH, INC.	+6.87%	25.78B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.34%	7.99B
SINOPHARM GROUP CO. LTD.	-2.79%	7.88B
HUADONG MEDICINE CO., LTD	-24.02%	7.62B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+21.83%	4.45B
EBOS GROUP LIMITED	-2.28%	3.89B
GALENICA AG	-3.51%	3.82B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+25.02%	3.69B

Pharmaceuticals Wholesale

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:58 2024-04-19 am EDT			5-day change	1st Jan Change
27.9 ^DKK	+0.36%		-3.14%	-19.22%

Apr. 09	H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	MT
Apr. 09	Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	CI

H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	Apr. 09	MT
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	Apr. 09	CI
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	Mar. 27	MT
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia	Mar. 27	CI
H. Lundbeck A/S Announces Management Appointments	Mar. 20	CI
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023	Mar. 20	CI
Transcript : H. Lundbeck A/S - Shareholder/Analyst Call	Mar. 20
H. Lundbeck Plans Clinical Development of Migraine Prevention Drug	Mar. 15	MT
H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage	Mar. 15	CI
H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023	Feb. 23	CI
H. Lundbeck A/S Announces Changes to Executive Management	Feb. 23	CI
Nordic Shares Dropped Tuesday; Lundin Gold Posted Biggest Loss	Feb. 13	DJ
Transcript : H. Lundbeck A/S, 2023 Earnings Call, Feb 07, 2024	Feb. 07
Transcript : H. Lundbeck A/S - Special Call	Jan. 31
Transcript : H. Lundbeck A/S - Special Call	Nov. 30

Lundbeck Nasdaq Copenhagen

Equities

LUN